Results for epivaccorona

Add to feed Create your own feed

Latest

A candidate Covid-19 vaccine known as EpiVacCorona, Russia’s second to be registered, proved “100 percent effective” in early-stage trials, a Russian consumer health watchdog has told local media. | @Reuters 

Russia's EpiVacCorona proved to be "100% effective" in early-stage trials, Russian consumer health watchdog Rospotrebnadzor told local media.

Efficacy of Russia's #EpiVacCorona  vaccine is 100 percent, watchdog says

“According to results of the first and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100%,” the Russian TASS news agency reported, citing Rospotrebnadzor.

tweet picture

EpiVacCorona, #Covid19  vaccine developed in #Russia , has 100% immunological efficacy, say reports | #CoronaVaccine 

Russia's second COVID-19 vaccine EpiVacCorona '100% effective': report

A candidate #COVID19  vaccine known as EpiVacCorona, #Russia ’s second to be registered, proved “100 percent effective” in early-stage trials.

tweet picture

epivaccorona'>Russian EpiVacCorona vaccine has no negative effect on health of embryo, watchdog says

UPDATE | Russian health minister says 1.5 mln+ doses of Sputnik V, 45,000 doses of Epivaccorona already rolled out #SputnikUpdates  @sputnikvaccine  #SputnikV 

epivaccorona'>Russian EpiVacCorona vaccine has no negative effect on health of embryo, watchdog says

Loading
Loading

Most relevant

Hot on the heels of Sputnik V, Russia’s 2nd #COVID  vaccine ‘EpiVacCorona’ set for release in December, say developers MORE:

#Putin : #coronavirus '>Firs #coronavirus  vaccine in the worl @sputnikvaccine  is already being used in RU . We registered another one – EpiVacCorona, a third vaccine is coming. Dozens of countries have already expressed interest in working together to organise supplies & joint manufacturing

tweet picture

Work in progress on a combined #Covid19 +flu vaccine in Novosibirsk-based centre of virology & biotechnology Vector. EpiVacCorona, Vector’s Covid19 vaccine provides immunity for up to 3 years, centre’s director said today. Earlier reports said the immunity was for up to 6+ months

tweet picture

EpiVacCorona, Russia's second #Covid19  vaccine made by Novosibirsk-based Vector centre of virology & biotechnology registered today. First 60,000 doses will be manufactured soon, post-registration clinical trials will start all around Russia with 40,000 volunteers involved

EpiVacCorona, Russia's 2nd #Covid19  vaccine created at Novosibirsk-based Vector to be registered by 15 Oct. Anna Popova, 59, head of consumer rights watchdog RosPotrebNadzor said that its perfect for 'older people & those with chronic diseases’ and that she herself got vaccinated

EpiVacCorona vaccine will be produced at Novosibirsk-based Vector's own production site, with the first batch for supply on the market to be manufactured in November. Third stage placebo-controlled trial will involve 30,000 volunteers starting at the end of October#Covid19Russia 

tweet picture

The second Russian vaccine, EpiVacCorona, should offer immunity for at least 6 months

Loading
Loading